Related Experiment Video
Updated: May 12, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Left Bundle Branch Area Pacing vs. Biventricular Pacing for Cardiac Resynchronization: Propensity Score Analysis
Fawzi Kerkouri1,2, Pierre Khattar3, Vincent Mansourati1
1Department of Cardiology University Hospital of Brest Brest France.
Background:
Left bundle branch area pacing (LBBAP) has emerged as a promising alternative to conventional biventricular pacing (BIVP) for cardiac resynchronization therapy (CRT). While previous data suggest LBBAP may provide superior outcomes, existing evidence needs more data.
Methods:
This retrospective study included all patients who underwent de-novo CRT at two centers in France (2022-2024). Procedural and clinical outcomes were compared between LBBAP and BIVP groups for de-novo CRT indications, using inverse probability weighting propensity score.
Results:
A total of 314 patients were included (75 LBBAP, 239 BIVP). Patients receiving LBBAP were older and more likely to have atrial fibrillation. Compared to BIVP, LBBAP was associated with shorter procedure time (96 vs. 128 min; p < 0.001), narrower paced QRS (128 vs. 139 ms; p < 0.001), and lower post-discharge device-related complications (1% vs. 11%; HR 0.10, 95% CI 0.01-0.84; p = 0.033). At 1-year, improvement in left ventricular ejection fraction (LVEF) was similar between groups (median ΔLVEF +15%; p = 0.438), as were hyper-response rates (52% vs. 60%; p = 0.231). After IPW-PS, no significant differences were observed in heart failure hospitalization (HR 0.99, 95% CI 0.40-2.64; p = 0.999), new-onset atrial fibrillation (HR 1.69, 95% CI 0.41-6.94; p = 0.492), sustained ventricular arrhythmias (HR 1.23, 95% CI 0.15-6.49; p = 0.828), overall (HR 1.10, 95% CI 0.44-2.62; p = 0.801), and cardiovascular deaths (HR 0.92, 95% CI 0.27-2.79; p = 0.927).
Conclusion:
LBBAP is associated with comparable resynchronization and clinical outcomes to BIVP, with fewer late complications.

